Today's Rundown CVS, Walgreens pledge to ramp up COVID-19 testing efforts as White House takes aim at reopening economy Merck, slower than its peers, edges into COVID-19 fight With sales team sidelined by COVID-19, Pfizer braces for a second-quarter revenue hit Merck, with a heavy presence in physician-administered drugs, predicts a $2.1B sales hit from COVID-19 AHA, AHIP team with U.S. Chamber urging Congress to protect coverage during pandemic Biopharma roundup: Pfizer CEO sees potential 2020 vaccine rollout; Merck braces for multibillion-dollar sales hit Healthcare roundup: AMA urges stronger federal leadership on testing, releases online resource hub on health equity Quest Diagnostics launches first consumer-ordered COVID-19 antibody test Novartis, already trialing hydroxychloroquine and Jakafi, plans COVID-19 testing for Ilaris House leadership: Next funding package on COVID-19 likely to target states, not hospitals Pfizer restarts trial recruitment, speeds up antiviral work against COVID-19 IQVIA: 80% of our trial sites are ‘inaccessible’ due to pandemic, eyes Q4 for turnaround Novartis' cholesterol buster, new trial starts fall victim to pandemic: report Despite COVID-19 and safety woes, Novartis still eyes blockbuster sales for Beovu Featured Story | | | Monday, April 27, 2020 The White House unveiled COVID-19 testing and tracing guidance Monday evening, with buy-in from many of the nation's largest pharmacy chains. |
|
|---|
|
Top Stories Tuesday, April 28, 2020 Almost all of Merck’s Big Pharma peers have either on their own or, increasingly, with a partner, geared up to fight the good fight against COVID-19. Tuesday, April 28, 2020 With a looming spinoff of its underperforming Upjohn generics business, Pfizer is working to get its branded drug unit in shape to strike out on its own. But with the novel coronavirus pandemic hamstringing its sales team, Pfizer might be due for a world of hurt in the coming quarter. Tuesday, April 28, 2020 While drugmakers across the industry deal with their respective COVID-19 challenges, Merck faces a unique set of circumstances because of its reliance on physician-administered drugs. Several companies have reaffirmed their 2020 revenue expectations, but Merck’s management just laid out expectations for a multibillion-dollar hit to 2020 sales. Tuesday, April 28, 2020 Top hospital, payer, physician and other healthcare industry groups are urging legislators to focus on coverage as they consider the next steps to combat COVID-19. Tuesday, April 28, 2020 Pfizer could be ready for emergency vaccine distribution this fall, its CEO said. Merck is expecting a multibillion-dollar sales hit thanks to its large stable of physician-administered drugs. Plus more headlines. Tuesday, April 28, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Tuesday, April 28, 2020 For about $120, anyone can get now get a COVID-19 antibody test from Quest Diagnostics. Tuesday, April 28, 2020 Another existing drug is being pitted against COVID-19. This time, Novartis is planning to study anti-inflammatory med Ilaris in a phase 3 trial to see if it can reverse severe immune overreactions in patients with COVID-19. Tuesday, April 28, 2020 The House Majority Leader gave details on the talks for the next round of stimulus funding for COVID-19, and it looks like states instead of hospitals will get the most attention. Tuesday, April 28, 2020 In its first-quarter results posted today, Big Pharma Pfizer said it is beginning to reopen some stalled trials and is now months ahead of schedule to develop a potential new med against COVID-19. Tuesday, April 28, 2020 As IQVIA released its first-quarter financials Tuesday morning, the CRO-analytics firm outlined just how hard its R&D business had been hit by the COVID-19 pandemic. Tuesday, April 28, 2020 The COVID-19 pandemic has driven biopharmas left and right to hit pause on clinical trials, and Novartis is no exception. The Swiss pharma has stopped enrolling patients in a trial of its cholesterol fighter inclisiran even as it expects its trials to stay on course in the long term. Tuesday, April 28, 2020 Novartis’ newly launched wet age-related macular degeneration med Beovu was hit by a double whammy: the negative impact of COVID-19 on the overall ophthalmology market and a new safety flag. But the Swiss pharma still sees it as a future blockbuster. |
